Herpes Zoster Market Research Report – Forecast till 2027

Herpes Zoster Market Research Report: by Diagnosis (laboratory testing, and others), Treatment and Prevention (Antiviral, Narcotic, Anti-Inflammatory, Antihistamines, Vaccines), Route of Administration (oral, others), End user - Forecast Till 2027

ID: MRFR/HC/5671-HCR | October 2022 | Region: Global | 90 Pages         

Herpes Zoster Market

Herpes Zoster Market at CAGR of 4.1% to hit $ 305.14 Million by 2030

Segmentation

By Diagnosis Laboratory Testing
By Treatment and Prevention Antiviral Narcotic Anti Inflammatory Antihistamines Vaccines
By Route of Administration Oral

Key Players

  • Astellas Pharma Inc.
  • Foamix Pharmaceuticals
  • GeneOne Life Science
  • GlaxoSmithKline plc
  • Merck & Co.
  • NAL Pharma
  • Novartis AG
  • Hoffmann-La Roche Ltd
  • TSRL Inc.

Drivers

  • Extensive research and development activities
Speak to Analyst Request a Free Sample

Herpes Zoster Market Overview:


Herpes Zoster Market is supposed to develop essentially over the gauge period. It is projected to grow at a CAGR of 12.7% over the estimated period. Herpes Zoster, otherwise called shingles, is a viral infection brought about by reactivation of varicella-zoster infection. It appears that reactivation of the varicella infection laid lethargic in the tangible ganglion following chickenpox contamination right off the bat throughout everyday life or periodically in utero. Postherpetic neuralgia (PHN) is one of the most annoying confusions, which is extremely tiring to the patient and the doctor.


Broad, innovative work exercises are key variables driving the Herpes Zoster market. On October 23, 2017, GlaxoSmithKline plc got FDA endorsement for Zoster Vaccine Recombinant, for example, Shingrix, to avoid herpes zoster in grown-ups matured 50 years and more established. Shingrix is a non-live, recombinant subunit antibody given intramuscularly in two dosages. Aside from this, there are numerous treatment approaches under clinical preliminaries to treat Herpes Zoster. For example, the ASP2151 drug by Maruho Co., Ltd., Asahi Kasei Pharma Corp., is under stage 3 clinical preliminary to treat patients impacted with Herpes Zoster.


Different factors like mechanical headways, geriatric populace, outstanding repayment and financing strategies in created nations, and creating medical services foundation are additionally expected to impel the development of the market. The significant expense of immunization and drugs, absence of consciousness of the illness among doctors in creating or immature nations, different scope of side effects, and different confusions can frustrate the market development over the figure time frame.


Segmentation:


The Herpes Zoster Market has been segmented into diagnosis, treatment & prevention, route of administration and end user.


The market, based on diagnosis, has been segmented into laboratory testing and others. The laboratory testing is further classified as immunofluorescent microscopy, real-time polymerase chain reaction (PCR), and serological testing.


The market, by treatment and prevention, has been segmented into diagnosis and treatment. The diagnosis segment is further classified as antiviral medications, narcotic medications, anti-inflammatory medications, antihistamines, anticonvulsants, capsaicin, numbing creams, gels, or patches, vaccines and others.


The market, by route of administration, has been segmented into oral, topical and others.


The market, by end user, has been segmented into hospitals & clinics, diagnostic centres, research & academic institutes, home care settings and others.


The hospitals and clinics segment is anticipated to hold the largest market share owing to increase in hospitalizations. The diagnostic centers are expected to grow at the highest CAGR owing to the increasing demand for modern healthcare facilities.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The herpes zoster market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European Herpes Zoster Market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The Herpes Zoster Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Herpes Zoster market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Herpes Zoster Market Share (%), by Region, 2017


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Report.


Geographically, the Americas is anticipated to dominate the herpes zoster market owing to increasing cases of herpes zoster, rising healthcare expenditure, geriatric population and technological advancements in herpes zoster. According to a 2017 study published in the Infectious Disease Clinics journal, more than 1 million cases of herpes zoster are registered in the United States every year which costs around USD 5 billion annually.


Europe is expected to hold the second largest position in the herpes zoster market. The market growth in this region is attributed to the government funding and improvement in research & development activities. In Europe, the annual incidence of herpes zoster varies from 2.0 to 4.6/1 000 and the overall incidence of herpes zoster is found to be increasing linearly.


The herpes zoster market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing awareness about the vaccines and rising healthcare spending.


The Middle East & Africa are expected to hold the least share of the market due to lack of awareness about the condition.


Herpes Zoster Market, by Diagnosis:



  • Laboratory Testing

    • Immunofluorescent Microscopy

    • Real-Time Polymerase Chain Reaction (PCR)

    • Serological Testing

    • Others




Herpes Zoster Market, by Treatment and Prevention:



  • Laboratory Testing

  • Antiviral Medications

  • Narcotic Medications

  • Anti-Inflammatory Medications

  • Antihistamines

  • Anticonvulsants

  • Capsaicin

  • Numbing Creams, Gels, or Patches

  • Vaccines

  • Others


Herpes Zoster Market, by Route of Administration:



  • Oral

  • Topical

  • Others


Herpes Zoster Market, by End User:



  • Hospitals & Clinics

  • Diagnostic Centres

  • Research & Academic Institutes

  • Home Care Settings

  • Others 


Herpes Zoster Market, by Region:



  • Americas

  • North America

  • US

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe

  • Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • The Middle East & Africa

  • Middle East

  • Africa


Herpes Zoster Market, by Key Players



  • Astellas Pharma Inc.

  • Foamix Pharmaceuticals

  • GeneOne Life Science

  • GlaxoSmithKline plc

  • Merck & Co.

  • NAL Pharma

  • Novartis AG

  • Hoffmann-La Roche Ltd

  • TSRL, Inc.


Recent Development


July 2021:


GlaxoSmithKline plc declared that the US Food and Drug Administration (FDA) had supported Shingrix (Zoster Vaccine Recombinant, Adjuvanted) to forestall herpes zoster in grown-ups matured 18 or more who are at a higher gamble of fostering the problem because of immunodeficiency.


 March 2020:


Camber Pharmaceuticals, Inc. reported the send-off of pregabalin containers, a conventional structure to ease torment made by nerve harm due to diabetes or shingles contamination.

Intended Audience



  • Research and Development Organization

  • Diagnostic Laboratories

  • Healthcare Organizations

  • Academics and Research Institutes

  • Pharmaceutical Companies



Report Scope:

Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   12.7% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment & prevention, Route of administration and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Astellas Pharma Inc., Foamix Pharmaceuticals, GeneOne Life Science, GlaxoSmithKline plc, Merck & Co., NAL Pharma, Novartis AG, Hoffmann-La Roche Ltd, TSRL, Inc.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   Extensive research and development activities


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The herpes zoster market would record a CAGR of 12.7% during the forecast period of 2018 to 2023.

Leading factors like the geriatric population, favorable reimbursement & funding policies in developed countries, technological advancements, and improving healthcare infrastructure would trigger market growth for the herpes zoster market.

The herpes zoster market study includes oral, topical, and others as the route of administrations.

The Americas would top the herpes zoster market.

The Asia Pacific region would be the fastest-growing herpes zoster market.